The Constitutional Calculus of Execution Protocol Failures
When an execution session fails—whether due to persistent inability to secure peripheral intravenous access, catastrophic venous extravasation, or improper pharmaceutical delivery—the legal framework governing subsequent state actions shifts into a contentious confluence of Eighth Amendment prohibition against cruel and unusual punishment, substantive due process, and statutory civil rights litigation under 42 U.S.C. § 1983.
The constitutional standard for execution challenges was profoundly altered by the United States Supreme Court's decisions in Baze v. Rees (2008), Glossip v. Gross (2015), Bucklew v. Precythe (2019), and clarified procedurally in Nance v. Ward (2022). Historically, the benchmark for Eighth Amendment challenges required demonstrating that a state's lethal injection protocol posed a "substantial risk of serious harm" or an "objectively intolerable risk of harm." Under current precedent, however, establishing medical vulnerability or severe risk alone does not suffice to enjoin an execution. An inmate challenging an execution protocol must satisfy a strict comparative standard.
The Two-Prong Glossip / Bucklew Standard
In Glossip v. Gross (576 U.S. 863) and reaffirming in Bucklew v. Precythe (139 S. Ct. 1112), the Supreme Court cemented an exacting evidentiary framework for capital condemned inmates challenging methods of execution:
- Prong 1: Substantial Risk of Severe Pain. The condemned must demonstrate that the state’s designated protocol creates a demonstrated risk of severe pain that is substantial when compared to known and available alternative methods. An "isolated mishap" or negligent execution attempt does not automatically establish an Eighth Amendment violation.
- Prong 2: Feasible and Readily Implemented Alternative. The inmate must plead and prove an alternative method of execution that is feasible, readily implemented, and in fact significantly reduces the substantial risk of severe pain. Crucially, the Supreme Court ruled in Bucklew that this alternative pleading requirement applies even when bringing an "as-applied" challenge based on an inmate's unique medical or anatomical condition.
- Nance v. Ward Procedural Clarification (2022): In Nance v. Ward (597 U.S. 159), the Supreme Court held 5-4 that an inmate may use 42 U.S.C. § 1983 rather than federal habeas corpus to challenge a lethal injection protocol by proposing an alternative method of execution (such as the firing squad) that is not currently authorized by state statute. This eliminated the jurisdictional trap that previously dismissed such challenges as improper successive habeas petitions.
Venous Access Compromise and Vascular Cutdown Litigation
A substantial portion of modern protocol litigation stems from medical and anatomical vascular collapse. Long-term incarceration, intravenous drug history, diabetes, hypertension, and natural aging frequently cause severe peripheral vein sclerosis. When execution teams attempt repeatedly to insert peripheral IV catheters—sometimes exceeding two hours and dozens of needle punctures—inmates experience excruciating soft-tissue trauma and psychological anguish.
In historical cases such as Romell Broom (Ohio, 2009) and Alva Campbell (Ohio, 2017), execution technicians repeatedly probed extremities without successfully establishing a patent line, forcing state governors to issue reprieves. Broom subsequently filed a constitutional challenge arguing that a second execution attempt would constitute cruel and unusual punishment under the Eighth Amendment and violate the Double Jeopardy Clause. The Ohio Supreme Court and federal courts ultimately rejected Broom's claim, citing the historical 1947 precedent Louisiana ex rel. Francis v. Resweber (329 U.S. 459), where the U.S. Supreme Court held that an unintended mechanical failure during an electrocution did not preclude the state from proceeding with a second, successful execution attempt.
Comparative Historical Case Precedents
| Inmate & Jurisdiction | Date & Mechanism | Protocol Failure Description | Judicial Ruling / Constitutional Holding |
|---|---|---|---|
|
Christa Pike Tennessee (2024–2026 Litigation) |
Lethal Injection / Pentobarbital | Severe peripheral vein collapse; challenges over compounding pharmacy secrecy and venous cutdown protocols. | Eighth Amendment § 1983 claims asserting lack of vascular access and drug degradation; stayed pending evidentiary hearings on alternative procedures. |
|
Kenneth Smith Alabama (2022–2024) |
IV Access Failure → Nitrogen Hypoxia | In November 2022, technicians spent four hours puncturing arms, hands, and collarbone without securing an IV line before calling off execution. | 11th Circuit permitted second attempt; Alabama subsequently executed Smith in January 2024 using nitrogen hypoxia gas protocol under Nance pleading. |
|
Clayton Lockett Oklahoma (2014) |
3-Drug Lethal Injection (Midazolam) | Femoral vein IV line collapsed, causing drug extravasation into subcutaneous tissue; inmate regained consciousness and died 43 minutes later of heart attack. | Prompted federal grand jury review, internal state investigation, and procedural protocols mandating strict ultrasound verification of vein patency. |
|
Alva Campbell Ohio (2017) |
Lethal Injection IV Punctures | Execution team attempted for nearly two hours to locate viable veins in arms and legs; severe chronic illness prevented catheterization. | Execution officially halted; Campbell died of terminal illness in prison while legal proceedings regarding alternative execution methods were pending. |
|
Romell Broom Ohio (2009) |
Lethal Injection Peripheral Veins | Over two hours, technicians punctured Broom 18 times without maintaining vein; governor granted one-week reprieve. | Ohio Supreme Court held 4-3 that a second execution attempt does not violate Double Jeopardy or Eighth Amendment under Francis v. Resweber. |
Compounded Drugs vs. Pharmaceutical Secrecy Acts
Major pharmaceutical manufacturers, primarily based in the European Union and the United States, instituted strict supply-chain controls preventing the use of FDA-approved midazolam, sodium thiopental, and pentobarbital in capital punishment. In response, executing states turned to non-FDA-approved compounding pharmacies to prepare custom single-dose barbiturates.
To protect compounding pharmacies from boycotts and liability, numerous states enacted execution secrecy statutes that shield the identity of suppliers, compounding chemists, and testing laboratories. Condemned inmates have challenged these secrecy laws under the First Amendment (freedom of information and public right of access) and the Fourteenth Amendment (due process). Federal circuit courts have routinely upheld state secrecy statutes, ruling that the Eighth Amendment does not create a freestanding right to discover execution drug formulas without an independent threshold showing of unconstitutional risk.